Experimental Model | Inducer of Injury | Mode of PARP Inhibition | Effect of PARP Inhibition | References |
---|---|---|---|---|
Rat cardiomyocytes | H2O2 | 3-AB | Improved cellular ATP levels, protection against the reduction of action potential durations | Bhatnagar, 1997 |
Rat cardiomyoblasts | H2O2, peroxynitrite, hypoxia reoxygenation | 3-AB, nicam, ISQ | Reduction of cell necrosis, improvement of mitochondrial respiration | Gilad et al., 1997; Bowes et al., 1999 |
Human cardiomyoblasts | H2O2 | 3-AB, nicam, ISQ | Reduction of cell death | Bowes et al., 1998a,b |
Mouse heart | Global I/R | PARP−/−phenotype | Reduction of NAD+ consumption, suppression of LV dysfunction | Grupp et al., 1999; Pieper et al., 2000 |
Rat heart | Global I/R | BGP-15, ISQ | Reduction of NAD+ and ATP catabolism, reduction of LV dysfunction | Docherty et al., 1999; Szabados et al., 2000 |
Rat heart | Global I/R | BGP-15,3-AB, nicam | Improved ATP and CK recovery | Halmosi et al., 2001 |
Rat heart | Global I/R | Lipoamide (antioxidant) | Reduction of myocardial damage | Szabados et al., 1999a |
Rat heart | Regional I/R | 3-AB | Decrease of infarct size | Bowes et al., 1999 |
Rabbit heart | Global I/R | 3-AB | Decrease of infarct size, reduction of LV dysfunction | Thiemermann et al., 1997 |
Mouse | Regional I/R | PARP−/−phenotype | Decrease of infarct size, neutrophil infiltration, and circulating IL-10, TNFα, and nitrate; reduction of P-selectin/ICAM-1 expression | Zingarelli et al., 1998; Yang et al., 2000 |
Mouse | IPC | PARP−/−phenotype | Suppression of the benefit of IPC | Liaudet et al., 2001c |
Rat | Regional I/R | 3-AB, GPI 6150 | Preservation of myocardial ATP stores, decrease of infarct size, reduction of LV dysfunction, reduction of neutrophil infiltration | Zingarelli et al., 1997a; Pieper et al., 2000; Liaudet et al., 2001b |
Rat | Regional I/R | 5-AIQ | Reduction of infarct size | Wayman et al., 2001 |
Rat | Heart transplant | 5-AIQ, PJ34 | Improved contractile function reduced ICAM-1 expression | Szabo et al., 2002 |
Rat | STZ diabetes | PJ34 | Improved contractile function | Pacher et al., 2002b |
Mouse | NOD diabetes | PJ34 | Improved contractile function | Pacher et al., 2002b |
Rat | Doxorubicin | PJ34 | Reduced myocyte death, improved contractile function, protection from mortality | Pacher et al., 2002a |
Mouse | Doxorubicin | PARP−/−phenotype | Improved contractile function | Pacher et al., 2002a |
Rabbit | Regional I/R | 3-AB, nicam, ISQ | Decreased infarct size | Thiemermann et al., 1997 |
Pig | Regional I/R | 3-AB, PJ34 | Decreased infarct size, improvement of LV function | Bowes et al., 1998b;Faro et al., 2001 |
Rat | Chronic ischemia | PJ34 | Reduced hypertrophy improved cardiac function | Pacher et al., 2002e |
LV, left ventricle; 3-AB, 3-aminobenzamide; 5-AIQ, 5-aminoisoquinolone; nicam, nicotinamide; I/R, ischemia-reperfusion; STZ, streptozotocin; IPC, ischemic preconditioning.